Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Javier Fernández-Jara
Observed name:
Javier Fernandez-Jara
Institutions:
Hospital Universitario Fundación Jiménez Díaz,
Universidad Autónoma de Madrid
Observed institutions:
Hospital Universitario Rey Juan Carlos,
Hospital Universitario Fundación Jiménez Díaz,
Hospital Universitario Severo Ochoa,
Universidad Autónoma de Madrid
ORCID:
0000-0003-3546-6356
Observed ORCID:
0000-0003-3546-6356
OpenAlex ID:
A5035220826
Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/CDKN2A
2023
·
Javier Martin-Broto
, Jeronimo Martinez-Garcia
, et al.
·
Signal Transduction and Targeted Therapy
·
51
PDF
Phase Ib Study for the Combination of Doxorubicin, Dacarbazine, and Nivolumab as the Upfront Treatment in Patients With Advanced Leiomyosarcoma: A Study by the Spanish Sarcoma Group (GEIS)
2024
·
Javier Martin-Broto
, Roberto Diaz-Beveridge
, et al.
·
Journal of Clinical Oncology
·
32
Remote cerebellar hemorrhage after lumbar spinal surgery
2010
·
Javier Fernandez-Jara
, Ana Jorge-Blanco
, et al.
·
Emergency Radiology
·
14
Factors associated with failed conservative treatment in patients with degenerative full-thickness supraspinatus tears: a prospective cohort study
2025
·
Natalia Martinez-Catalan
, Santiago Gabardo-Calvo
, et al.
·
The Bone & Joint Journal
·
3
Arthroscopy has a higher discriminative capacity than MRI in detecting mild cartilage lesions
2024
·
Irene Sánchez-Platero
, Javier Fernández-Jara
, et al.
·
Rheumatology
·
2
PDF
Supplementary Table S3 from Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma
2026
·
Javier Martin-Broto
, Javier Martinez-Trufero
, et al.
Supplementary Table S1 from Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma
2026
·
Javier Martin-Broto
, Javier Martinez-Trufero
, et al.
Supplementary Table S2 from Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma
2026
·
Javier Martin-Broto
, Javier Martinez-Trufero
, et al.
Data from Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma
2026
·
Javier Martin-Broto
, Javier Martinez-Trufero
, et al.
Supplementary Figure S1 from Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma
2026
·
Javier Martin-Broto
, Javier Martinez-Trufero
, et al.
Supplementary Figure S2 from Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma
2026
·
Javier Martin-Broto
, Javier Martinez-Trufero
, et al.
Prognostic significance of HMGB1 expression as a biomarker of immunogenic cell death in patients with leiomyosarcoma and undifferentiated pleomorphic sarcoma treated with chemo-immuno–based regimens.
2026
·
David Silva Moura
, Jose Lucinio Mondaza-Hernandez
, et al.
·
Journal of Clinical Oncology
PDF
Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma
2026
·
Javier Martin-Broto
, Javier Martinez-Trufero
, et al.
·
Clinical Cancer Research
Show more works
View as search
Works count:
13
Citation count:
102
H-index:
3
I10-index:
3
Year
Topic
Type